학술논문
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Document Type
article
Author
Source
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab. Authors here show that the change in levels of the chemokine CXCL13 shortly following the start of siltuximab treatment is predictive of response.